2017 CO Election Results for Cannabis Issues, FDA CBD Warning Letters, HLG Sets Sights Abroad
Complete Colorado Election Results for 2017 Cannabis Issues
A Colorado city known for its cantaloupes will soon be known for its recreational cannabis. Three cities in southern Colorado — Alamosa, Monte Vista and Rocky Ford, all located south of Pueblo — voted Tuesday on whether to allow sales of medical marijuana, recreational marijuana or both; they also had separate, corresponding tax measures for collecting revenue on prospective cannabis sales. Read More.
Hemp Lawyer: FDA CBD Warning Letters Shouldn't Alarm Industry
FDA last week reminded four companies that it won’t tolerate claims that CBD-containing foods and dietary supplements treat diseases such as cancer, highlighting the potential perils of sharing consumer testimonials. The warning letters also reinforced FDA’s view that CBD (cannabidiol) cannot be sold in dietary supplements, or added to food, under the Federal Food, Drug and Cosmetic Act (FD&C). Read More.
Colorado Leads Country in Hemp Production, a Growing Field
Dispensaries might get all the attention, but hemp farmers are getting the acreage – 23,343 acres, to be exact, according to a new study by Vote Hemp, an organization dedicated to advancing the industrial hemp industry. And which state is leading the pack? Colorado, by far. Read More.
Cannabis Firm Hoban Law Sets Sights Abroad
Hoban Law Group, a Denver-based firm focused on advising the emerging legal and medical cannabis industry, has announced plans to expand internationally, saying it would open four European and two Latin American offices by spring 2018. Pointing to a rapidly evolving marketplace for its clients in the regulated marijuana dispensary and industrial hemp spaces, Hoban Law—which has 34 lawyers and dubs itself a “cannabusiness” law firm—laid out the expansion plans in a statement on Monday. Read More.
“A Significant Event”: CBD-based Pharma Drug Epidiolex Presented to FDA for Approval
A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Read More.